Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure

Table 2 Clinicopathological characteristics of 101 hepatitis B virus-related cirrhotic patients with hepatocellular carcinoma

	Patients with	Patients without	P value
	Liver failure, n = 15	Liver failure, n = 86
Sex			0.439
Male	9 (90)	50 (89)
Female	1 (10)	6 (12)
Age in yr	55 (22-78)	55 (40-67)	0.958
Primary tumor
Tumor size in mm12	59 (15-154)	38 (10-197)	0.069
Single, n	4 (27)	60 (70)
Multiple in n	11 (73)	26 (30)
Baseline serological index1
Aspartate aminotransferase in IU/L	59 (17-116)	33 (17-1663)	0.030
Alanine aminotransferase in IU/L	34 (17-98)	31 (11-1491)	0.248
Total bilirubin in mg/dL	18.2 (8.2-37.9)	15.7 (3.2-35.5)	0.314
Albumin in g/L	38.7 (30.9-45.8)	40.3 (23.0-50.3)	0.135
Alkaline phosphatase in U/L	131 (71-365)	91 (41-410)	0.004
Platelet as /L	200 (111-496)	188 (49-489)	0.462
Prothrombin time in s	12.8 (11.3-14.9)	12.3 (10.6-16.8)	0.138
Cholinesterase in U/L	6271 (2522-8417)	6714 (2334-12360)	0.110
ICG test1
Elimination rate constant in K as min-1	0.13 (0.09-0.19)	0.21 (0.12-0.29)	0.308
Retention rate at 15 min as R15 in %	8.2 (1.3-28.4)	12.8 (6.1-18.0)	0.002
The half-life as T1/2 in min	6.36 (3.73-7.88)	3.27 (2.39-5.68)	0.061
Baseline score
Child-Pugh classification			0.786
A	15 (100)	81 (94)
B	0 (0)	5 (6)
C	0 (0)	0 (0)
Fibrosis grade on specimen			0.174
F1	1 (7)	9 (11)
F2	0 (0)	8 (9)
F3	0 (0)	7 (8)
F4	9 (60)	14 (16)
N/A	5 (33)	48 (56)

Data are numbers of patients, with percentages in parentheses, except otherwise indicated.

¹Numbers in parentheses are ranges;

²If the number of lesions is greater than 2, the largest lesion was chosen to measure the maximal dimension. N/A: Not available.